companies / aqualungtherapeutics-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 3,000,0003.0M | ○ |
|---|---|---|
| founded | 2014 | |
| hq | JUNO BEACH, Florida, USA | |
| industry | unknown | |
| stage | null |
Clinical-stage biopharma developing the ALT-100 monoclonal antibody for ARDS and progressive pulmonary fibrosis (interrupting eNAMPT/TLR4 signaling). Targets ARDS, fibrosis, and vascular-leak patient populations and pharma partners. FDA-cleared Phase 2a fibrosis study and PUERTA Phase 2a ARDS data presented in 2026 with NIH STTR support.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2023-09-01 | grant | 3,000,0003.0M | null | ○ |
Afterpay, Sentry, Squarespace, Squarespace Commerce, Stimulus, parallax.js, Vercel Speed Insights, web-vitals, moment 0, @sentry/browser
| fact | status | src |
|---|---|---|
| Grant, $3.0M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes